Key iron death genes can predict the efficacy of neoadjuvant chemotherapy for breast cancer

Key iron death genes can predict the efficacy of neoadjuvant chemotherapy for breast cancer

Key iron death genes can predict the efficacy of neoadjuvant chemotherapy for breast cancer

Recently, the team of Lu Jinsong, director of the Department of Breast Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, revealed for the first time that the important genes ACSL4 and GPX4 that regulate iron death can be used as new predictive and prognostic biomarkers for breast cancer patients receiving neoadjuvant chemotherapy
.

The imbalance between the two may indicate the degree of iron death induced by neoadjuvant chemotherapy in breast cancer cells, and independently predict whether the patient can achieve complete pathological remission and tumor-free survival.

EBioMedicine

Ferroptosis (Ferroptosis) is a newly discovered form of programmed cell death in recent years.
It is characterized by an iron-dependent way of active programmed cell death, which is different from the forms of apoptosis, cell necrosis and autophagy.

.

The abnormal production of iron death may be the cause of the occurrence and development of many diseases, and the imbalance of its regulation in tumor cells may be one of the important mechanisms of chemotherapy resistance

Previous basic studies have found that the genes ACSL4 and GPX4 are key genes that regulate the occurrence of iron death
.

A variety of tumor treatment methods including chemotherapy, targeted therapy and radiotherapy can in principle induce iron death of cancer cells, but for breast cancer patients receiving the same treatment mode, which patients can effectively induce iron death and manifest as clinical lesions Relieving and improving the survival rate, especially how to effectively predict the efficacy of neoadjuvant chemotherapy in breast cancer is an important clinical topic that needs to be resolved urgently

In order to solve this scientific problem, the researchers analyzed the relationship between the important iron death genes ACSL4 and GPX4 and the efficacy of neoadjuvant chemotherapy for breast cancer
.

The study included patients who participated in a prospective neoadjuvant clinical trial conducted by the Department of Breast Surgery of Renji Hospital.

At the same time, researchers have also observed for the first time that the combined level of ACSL4/GPX4 has a better predictive value for pathological complete remission in patients without family history, which may mean that for breast cancer patients without family history, iron death may be platinum-containing Chemotherapy induces the main mode of tumor cell death
.

In addition, the study also explored the pathways through which ACSL4 and GPX4 affect the efficacy of neoadjuvant chemotherapy for breast cancer through bioinformatics analysis, and verified related gene changes through in vitro experiments

Lu Jinsong said that in the future, prospective, large-sample, randomized clinical trial design will be needed to further explore the effect of iron death gene on the efficacy of neoadjuvant chemotherapy for breast cancer patients, so that it is expected to use iron death gene testing to screen neoadjuvant chemotherapy options.
Potential responders to guide the decision-making of chemotherapy regimens
.

(Source: Huang Xin, China Science News)

Related paper information: https://doi.

https://doi.
org/10.
1016/j.
ebiom.
2021.
103560